Condition
Rectal Mucinous Adenocarcinoma
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results50% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Terminated2
Completed2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00745134Phase 2TerminatedPrimary
Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer
NCT01802320Phase 2Completed
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
NCT00068692Phase 3CompletedPrimary
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
NCT01198535Phase 1Terminated
Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
Showing all 4 trials